Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EVALUATION OF CONTINUOUS-INFUSION SURAMIN IN METASTATIC BREAST-CANCER- IMPACT ON PLASMA-LEVELS OF INSULIN-LIKE GROWTH-FACTORS (IGFS) AND IGF-BINDING PROTEINS
Autore:
LAWRENCE JB; CONOVER CA; HADDAD TC; INGLE JN; REID JM; AMES MM; SUMAN VJ; MARKS RS; ERLICHMAN C; HARTMANN LC;
Indirizzi:
MAYO CLIN & MAYO FDN,ENDOCRINE RES UNIT,200 1ST ST SW ROCHESTER MN 55905 MAYO CLIN & MAYO FDN,ENDOCRINE RES UNIT ROCHESTER MN 55905 MAYO CLIN & MAYO FDN,DEPT ONCOL ROCHESTER MN 55905 MAYO CLIN & MAYO FDN,BIOSTAT SECT ROCHESTER MN 55905
Titolo Testata:
Clinical cancer research
fascicolo: 10, volume: 3, anno: 1997,
pagine: 1713 - 1720
SICI:
1078-0432(1997)3:10<1713:EOCSIM>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
I SOMATOMEDIN RECEPTOR; PHASE-I; CELLS; INHIBITION; HORMONE; SERUM; PROTEOLYSIS; TUMOR; VIVO; STIMULATION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
37
Recensione:
Indirizzi per estratti:
Citazione:
J.B. Lawrence et al., "EVALUATION OF CONTINUOUS-INFUSION SURAMIN IN METASTATIC BREAST-CANCER- IMPACT ON PLASMA-LEVELS OF INSULIN-LIKE GROWTH-FACTORS (IGFS) AND IGF-BINDING PROTEINS", Clinical cancer research, 3(10), 1997, pp. 1713-1720

Abstract

Suramin represents a new class of antitumor drugs that targets growthfactor networks, In this Phase II trial, suramin was administered by continuous infusion to 10 patients with advanced breast cancer, The target level of 280 mu g/ml suramin was achieved in a median of 10 days;toxicities in this patient group were low, We monitored the insulin-like growth factor (IGF) network in these patients because of the previously defined growth-promoting role of the IGFs in breast cancer, Plasma levels of total IGF-I and total IGF-II showed variable responses tosuramin with median decreases of 24 and 23%, respectively, for the 10patients; for total IGF-I levels, this did not reach statistical significance, On the other hand, free IGF-I plasma levels were consistently and dramatically increased (over 250%) after suramin infusion, IGF-binding proteins (IGFBPs), modulators of IGF bioavailability, were alsomeasured. Levels of IGFBP-3, the major carrier of IGFs in the circulation, were decreased 21% after suramin treatment when measured by immunoradiometric assay, However, the majority of the plasma IGFBP-3 remaining after suramin was not the intact high-affinity IGF-binding form but rather a 30-kDa fragment with markedly reduced affinity for IGF-I, IGFBP-3 protease activity was evident in the plasma of 3 of 10 patients after suramin, Measurements of plasma IGFBP-1, IGFBP-2, and IGFBP-4 revealed no significant changes in response to suramin. The dramatic increase in active free IGF-I seen after suramin raises concern and underscores the importance of measuring relevant biomarkers in clinical trials.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/07/20 alle ore 18:12:40